宜宾哪种双眼皮好宜宾哪个医院祛斑最好,宜宾微创开双眼皮副作用,医院开双眼皮恢复时间宜宾,宜宾润百颜玻尿酸好的医院,宜宾开一个眼角的费用是多少,宜宾胸部缩小多少钱,宜宾双眼皮贴一般多少钱

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

DAMASCUS, Sept. 21 (Xinhua) -- The national archeological expedition recently discovered a gigantic building built with large-size hewn stones that date back to the Roman era, Syrian Arab News Agency (SANA) said Wednesday.The building, the thickness of its walls up to 1.5 meters, was found at Qumet Nibal site in the northeastern province of Raqqa, said SANA.Ibrahim Kheir Bek, head of the archeological department in the area, told SANA that the excavation unearthed a 6-meter-long entrance to the building, adding that works are still underway in the site.A day earlier, the national archeological expedition discovered a mosaic dating back to the 6th century A.D. in northeast Syria, SANA said, adding that the rectangular mosaic was found at Hwaija Halawa site on the banks of al-Assad Lake in Raqqa province.Ayham al-Fakhri, head of the national expedition, was quoted by SANA as saying that the expedition uncovered 58 square meters of the mosaic with various colorful geometric shapes.

SUVA, Sept. 21 (Xinhua) -- The Secretariat of the Pacific Community (SPC) stressed on Wednesday that sustainable use and management of forests and tree resources will remain its important focus for the foreseeable future.Sairusi Bulai, a forestry team coordinator of SPC's Land Resources Division (LRD) told a regional workshop currently underway in Fiji's western tourist city of Nadi that "our main issue was and continues to be the lack of adequate resources to enable countries to effectively implement sustainable forest management.""Therefore, we are very fortunate that we have this opportunity to discuss findings and recommendations of the mission, which the UN-REDD Program has undertaken in the Pacific earlier this year," he added.REDD+ is a new international mechanism to compensate developing countries for reducing their rate of deforestation and forest degradation and increasing their carbon stocks.Developing countries participate on a voluntary basis. They provide technical and financial assistance to enable eligible countries to meet the requirements for future participation. Once a country begins participating, it receives compensation for its verified reduction in carbon emission from forest activities.The UN-REDD Program is a collaborative partnership of the United Nations Development Program (UNDP), the United Nations Environment Program (UNEP) and the Food and Agriculture Organization (FAO) to support countries in the preparation of this mechanism.Bulai encouraged participants to take advantage of the excellent opportunity to discuss REDD+ experiences in the region and to link up with the experts in attendance.REDD+ gives an excellent opportunity to create better awareness and understanding amongst all stakeholders, including resource owners, so that informed decisions are made to avoid exploitation, he said.Bulai, meanwhile, stressed on the critical importance of multi- sectoral as well as multi-stakeholder based approaches to forest management to effectively reduce deforestation and forest degradation.

HAVANA, Sept. 6 (Xinhua) -- Cuban medical authorities have launched the sales of the world's first therapeutic vaccine against lung cancer, local officials said on Tuesday.The CimaVax-EGF vaccine, as a result of a 25-year research into diseases related to tobacco smoking, has been developed by researchers and scientists at the Center of Molecular Immunology (CIM) in Havana.The active drug ingredient in the vaccine is based on "a protein we all have when cancer is uncontrolled." "The epidermal growth factor is related to all cell proliferation," said Gisela Gonzalez, head researcher of the project."The drug could turn the cancer into a manageable, chronic disease by generating antibodies against the proteins which triggered the uncontrolled cell proliferation," she said.The immunogenic vaccine is appropriate to patients with advanced lung cancer in stages of three and four, showing no positive response to other kinds of treatments such as chemotherapy and radiotherapy, the expert said."It is not possible to prevent the disease but this vaccine improves significantly the status of the critically ill patients," she added.She said the CimaVax-EGF has gone through clinical studies and trials in over 1,000 patients across the island and is currently distributed free of charge in all hospitals of the Caribbean island nation.Gonzalez also said researchers at the CIM planned to use the same principle of the CimaVax-EGF in treating other cancerous tumors such as prostate, uterus and breast cancers.Lung cancer is regarded as one of the world's most serious, common and deadly cancers and is most frequently found among tobacco smokers.According to the World Health Organization, the disease generally kills 5 million people a year, and the figure is expected to rise to as much as 8 million by 2030 unless smoking habits are changed.In Cuba, like many other developing countries across the world, smoking is seen as a status symbol. Lung cancer, killing about 20,000 people a year in the Caribbean country, is considered a serious threat to public health and the leading cause of death in 12 of the country's 15 provinces.